We bring you the best papers in medicine, daily in your inbox - for free!
Subscribe 👉 https://www.stitches.today/medicine
Early diagnosis and tailored treatment of adolescent PCOS are crucial for long-term health, emphasizing lifestyle changes and meticulous monitoring.
by Machado IFR, Tinano FR, Latronico AC and Gomes LG in J Clin Endocrinol Metab
📖 read the article: https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/clinem/dgag198/8675166?redirectedFrom=fulltext
Elevated serum vitamin A and RBP4 levels correlate with increased severity of metabolic dysfunction-associated steatotic liver disease in patients.
by OuYang D, Peng X (...) Zhang Y et 2 al. in J Nutr
📖 read the article: https://www.sciencedirect.com/science/article/pii/S0022316626002397?via%3Dihub
FDA shifts focus from comparative efficacy studies to analytical assessments for evaluating biosimilars in hematology, enhancing approval confidence.
by Herndon T, Brahme NN and Ricci MS in Blood
📖 read the article: https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2025031673/568328/Biosimilars-approved-for-hematologists-lessons?redirectedFrom=fulltext
T cell responsiveness evolves through self-peptide interactions, refining their activation threshold and shaping immune responses to foreign antigens.
by Mandl JN, Melichar HJ (...) Klein L et 2 al. in Nat Rev Immunol
📖 read the article: https://www.nature.com/articles/s41577-026-01305-2
T cells integrate signals from self-ligands not only during thymic development but also as they circulate through secondary lymphoid organs. These encounters with self in the periphery shape their activation and function, thereby ‘training’ T cells to interpret and respond to foreign antigens.
Olaparib plus radium-223 significantly boosts radiographic progression-free survival in men with castration-resistant prostate cancer and bone metastases.
by McKay RR, Xie W (...) Shapiro GI et 19 al. in J Clin Oncol
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-02835?cookieSet=1
Aluminium adjuvants in vaccines show no significant health risks; localized reactions are rare and self-limited, say researchers.
by Doyon-Plourde P, Chong J (...) Zafack J et 4 al. in BMJ
📖 read the article: https://www.bmj.com/content/393/bmj-2025-088921
Objective To systematically review and critically appraise human evidence on potential health effects of aluminium adjuvanted vaccines. Design Systematic review following PRISMA (preferred reporting items for systematic review and meta-analysis) 2020 guidelines. Data sources Six databases and trial registries were searched from inception to 3 March 2023 then updated to 27 November 2025. Reference lists of eligible studies were also screened. Eligibility criteria for selecting studies Human studies assessing health outcomes after aluminium adjuvanted vaccination, including randomised controlled trials, cohort studies, case series, and ecological studies. Investigational vaccines, case reports, and review articles were excluded. Data extraction and synthesis Two reviewers screened studies (with AI assistance for the 2023-25 update), extracted data, and assessed risk of bias (using RoB 2.0, ROBINS-I, or an adapted tool for case series). Certainty of evidence was rated using GRADE (Grading of Recommendations Assessment, Development, and Evaluation). Results The review included 59 studies (37 case series, 11 randomised controlled trials, nine cohort studies, two ecological studies). High quality evidence from randomised controlled trials and large cohorts consistently showed no association between aluminium adjuvanted vaccines and serious or long term health outcomes, such as asthma, autism spectrum disorders, or other chronic conditions. Studies on macrophagic myofasciitis were generally small and methodologically limited, and did not provide credible evidence of a causal association (very low certainty). Localised persistent nodules or granulomas were observed infrequently after diphtheria-tetanus-pertussis vaccines, consistent with delayed type hypersensitivity (<1%, self-limited; moderate to low certainty). For common adverse events (eg, headache, myalgia), high certainty randomised controlled trials found no consistent increase in risk with aluminium adjuvanted formulations. When differences were observed, they were small and predominantly mild to moderate in severity. Evidence was dominated by methodologically limited studies, with most case series and ecological studies at serious or critical risk of bias. Conclusions are primarily supported by higher quality randomised controlled trials and cohort evidence. Conclusions Current evidence does not support causal associations between aluminium adjuvanted vaccines and serious or long term health outcomes. The most consistently documented reactions were persistent nodules or granulomas that are uncommon, local, and self-limited hypersensitivity reactions. These findings are broadly consistent with post-licensure surveillance findings. The predominance of methodologically limited studies for some outcomes highlights the need for higher quality research. Systematic review registration PROSPERO CRD42023462831. All data underlying this systematic review were extracted from studies that are already publicly available. The data extraction form, risk of bias assessments, and GRADE certainty assessments are provided in the supplementary materials. Reconciled extracted data are available upon request.
Neutrophils restrict immunosuppressive macrophages in pancreatic cancer liver metastases, offering new targets for therapeutic interventions in PDAC.
by Belz L, van den Heuvel D (...) Stark K et 25 al. in Gastroenterology
📖 read the article: https://linkinghub.elsevier.com/retrieve/pii/S0016508526068186
Ketamine Infusions Rapidly Alleviate Suicidal and Depressive Symptoms in Major Depressive Episodes, with Minimal Side Effects.
by Shim SR, Jeong HS (...) Rhee TG et 7 al. in JAMA Psychiatry
📖 read the article: https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2848531
Colonoscopy screening cuts colorectal cancer incidence by 19%, but shows no significant impact on mortality after 13 years.
by Kaminski MF, Kalager M (...) Bretthauer M et 19 al. in Lancet
📖 read the article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00508-8/abstract
Older adults with prior adenomas face slightly higher colorectal cancer risks, but non-CRC mortality vastly overshadows these threats.
by Gupta S, Liu L (...) May FP et 15 al. in JAMA
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2847311
